Invictus and Cannamerica Provide Update on Hemp and CBD Joint Venture

INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV:GENE; OTC:IVITF; FRA:8IS1) is pleased to provide an update on its binding letter of intent to create a joint venture with Cannamerica Brands Corp. (CSE:CANA) (OTC:CNNXF) and CBDistribution Company Ltd. (collectively, the “Joint Venture”) that was previously announced on January 7, 2019, with the intention of acquiring hemp biomass for extraction into CBD isolate using purpose-built facilities for large scale CBD extraction.

The transaction is anticipated to close on or before March 31, 2019. Each of the parties involved have received approval from their respective Board of Directors to enter into the Joint Venture. Once the transaction is closed, the Joint Venture will mark the Company’s entry into the CBD market in the United States. The Joint Venture will no longer be purchasing eighty percent (80%) of the membership interests of Z3 Sciences, LLC, as previously announced on January 16, 2019, due to a mutual decision made by all parties involved.

Invictus has also granted 450,000 incentive stock options to certain consultants of the Company. Each stock option has an exercise price of $0.95 and is exercisable into one common share of the Company. The options vest immediately and are exercisable over a period of five years. The stock options were granted subject to the terms and conditions of the Company’s Stock Option Plan.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director

Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(833) 879-4363

About Invictus

Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated route-to-customer approach is defined by five pillars of sales and distribution including medical, adult-use recreational, retail, Licensed Producer to Licensed Producer and international.

Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with three cannabis production facilities licensed under the Cannabis Act and Cannabis Regulations in Canada. To accommodate domestic and international sales, Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd., is well advanced in building its Phase 3 purpose-built cultivation facility to be European Union Good Manufacturing Practices compliant. The Company is targeting for up to 50 percent of its production to comprise medical cannabis. To ensure consistency in quality and supply, Invictus participates in all aspects of the growing process through its subsidiary, Future Harvest Development Ltd., a high-quality fertilizer and nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 70 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. For more information visit www.invictus-md.com.

About CannAmerica Brands Corp.

CannAmerica Brands is a U.S. marine veteran founded and operated portfolio of cannabis brands with licensing agreements in the states of Colorado, Nevada and Maryland. The Company aims to maximize the value of its brands by employing strong brand management teams, marketing and licensing the brands through various distribution channels, including dispensaries, wholesalers and distributors, in the United States and internationally. The Company’s core strategy is to enhance and monetize the global reach of its existing brands, and to pursue additional strategic acquisitions to grow the scope and diversity of its brand portfolio. For more information, please visit www.cannamericabrands.com

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including that the Joint Venture transaction is anticipated to be completed on or before March 31, 2019 and that the Joint Venture Transaction is expected to close as anticipated by management are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Joint Venture transaction will be completed on or before March 31, 2019 and that the Joint Venture transaction will close as anticipated by management.  These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that the Joint Venture transaction will not be completed on or before March 31, 2019, that the Joint Venture transaction will not be completed as expected by management and that there is no guarantee the Joint Venture transaction will close at all.  Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Jessica Martin

Invictus

(833) 879-4363

jessica@invictus-md.com

Click here to connect with Invictus (TSXV:GENE, OTC:IVITF) for an Investor Presentation.

Source: globenewswire.com